Tag: cardio-oncology
-
Heart Failure in AML: New Evidence Emerges
New Evidence on Cardiotoxicity in AML Treatment A comprehensive new systematic review analyzed 41 studies involving 5,995 patients with acute myeloid leukemia (AML) who received anthracycline-based regimens during remission induction. The pooled rate of heart failure in this population was 3.2%, with notable differences depending on the anthracycline used: 2.3% with daunorubicin, 5.0% with idarubicin,…
-
New Evidence on Heart Failure in AML Treated with Anthracyclines: What Clinicians Need to Know
Overview Heart failure in AML remains a critical concern for patients undergoing induction therapy with anthracycline-based regimens. A comprehensive meta-analysis led by researchers in the Netherlands analyzed 41 studies totaling 5,995 AML patients. The study quantified the burden of heart failure and highlighted substantial variability depending on the specific anthracycline used. These findings reinforce the…
-
Early-Onset Breast Cancer: Perlmutter Experts Explain Rising Rates in Younger Women
Understanding the Rise of Early-Onset Breast Cancer Breast cancer remains a leading health concern for women, and disturbing trends show younger patients being diagnosed at more advanced stages. At NYU Langone’s Perlmutter Cancer Center, experts stress that early-onset breast cancer—diagnoses in women under 50—requires tailored strategies in screening, prevention, and education. While 20- to 49-year-olds…
-
Perlmutter Cancer Center Experts Highlight Rising Early-Onset Breast Cancer and New Support Programs
H2: Rising tide of early-onset breast cancer in the United States P: Breast cancer remains the leading cause of cancer death among women aged 20 to 49 in the United States. At NYU Langone’s Perlmutter Cancer Center, doctors report that younger patients are being diagnosed at more advanced stages, underscoring the urgent need for improved…